宁波三星医疗电气股份有限公司 董事会审计委员会2023年度履职情况报告 各位董事： 根据《上市公司治理准则》、《上海证券交易所股票上市规则》、《上海证 券交易所上市公司自律监管指引第1号——规范运作》和《宁波三星医疗电气股 份有限公司章程》、《审计委员会议事规则》的有关规定，作为宁波三星医疗电 气股份有限公司（以下简称"公司"）现任审计委员会成员，现就2023年度履职 情况向董事会作如下报告： 一、 审计委员会基本情况 公司第五届董事会审计委员会由独立董事王溪红女士、段逸超先生及董事沈 国英女士3名成员组成，经公司2020年6月9日召开的第五届董事会第一次会议选 举产生，主任委员由具有专业会计资格的独立董事王溪红女士担任。 三、 审计委员会履职情况 （一）监督及评估外部审计机构工作 公司聘请的立信会计师事务所（特殊普通合伙企业）具有执行证券、期货相 关业务的资格，具有较强的专业能力。立信会计师事务所严格按照国家有关规定 及注册会计师执业规范的要求开展审计工作，坚持独立、客观、公正的审计准则， 恪尽职守、勤勉尽责，较好完成了公司委托的年度财务会计报告审计工作及其他 各项业务。 根据立信会计师事务所在报告期内的履 ...

经立信会计师事务所（特殊普通合伙）审计，截至2023年12月31日，宁波三星医 疗电气股份有限公司（以下简称"公司"）母公司期末未分配利润为人民币 2,099,045,890.36元。经公司第六届董事会第十二次会议、第六届监事会第九次会议审 议通过，公司2023年度拟以实施权益分派股权登记日登记的总股本为基数进行现金分 红。本次利润分配预案如下： 证券代码：601567 证券简称：三星医疗 公告编号：临 2024-049 宁波三星医疗电气股份有限公司 关于2023年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、利润分配预案内容 重要内容提示： 公司拟以本次实施权益分派股权登记日登记的可参与利润分配的总股数为基数， 向全体股东每10股派发现金红利（含税）6.50元。截至本公告披露日，公司总股本为 1,411,197,171股，扣除回购专用账户股份13,559,332股，公司可参与利润分配的总股数 为1,397,637,839股，以此计算预计合计派发现金红利约人民币908,464,595.35元（含 税 ...

Dividends and Share Repurchases - The company plans to distribute a cash dividend of RMB 6.50 per 10 shares, totaling approximately RMB 908,464,595.35[2] - The total cash dividend, including share repurchases, amounts to RMB 960,832,171.85, representing 50.47% of the net profit attributable to shareholders[2] - The company's total share capital is 1,411,197,171 shares, with 13,559,332 shares repurchased[2] - The company's 2023 dividend plan is to distribute a cash dividend of 6.50 yuan per 10 shares, with an estimated total cash dividend of approximately 908,464,595.35 yuan[151] - Including the 52,367,576.50 yuan spent on share repurchases, the total cash dividend for 2023 is 960,832,171.85 yuan, accounting for 50.47% of the net profit attributable to shareholders[152] - Cash dividend amount (including tax) is RMB 908,464,595.35, accounting for 47.72% of the net profit attributable to ordinary shareholders of the company[154] - Total dividend amount (including tax) is RMB 960,832,171.85, accounting for 50.47% of the net profit attributable to ordinary shareholders of the company[155] - The company completed the registration of 4.675018 million restricted shares for the fourth and fifth phases of the restricted stock incentive plan[156] - 581,500 restricted shares were repurchased and canceled due to 24 incentive objects leaving the company[156] - 8,344,200 restricted shares were released for the first time, with a release ratio of 40%[156] - 872,900 restricted shares were repurchased and canceled due to 18 incentive objects leaving the company[157] Subsidiaries and Investments - The company's subsidiaries include Samsung Smart, Ningbo Lianneng, and Samsung Hong Kong, among others[6] - The company has a significant presence in the medical and rehabilitation sectors with subsidiaries like Ningbo Mingzhou Hospital and Wenzhou Shenlan Hospital[6] - The company has multiple wholly-owned subsidiaries including Ningbo Sanxing Medical Research Institute, Nansen Instrumentos De Precisao Ltda in Brazil, and Sanxing Smart Electric Bangladesh Co. Ltd[8] - Key subsidiaries also include Ningbo Sanxing Electric (Sweden) AB, Foxytech Sp. z o.o., and NANSEN PERU S.A.C[8] - The company holds equity stakes in various partnerships such as Ningbo Sanxing Kaiyun Medical Investment Partnership and Beijing Chunfeng Bairun Equity Investment Partnership[8] - Major subsidiaries in the energy sector include Ningbo Aogao Supply Chain Co., Ltd., Ningbo Aogao Power Development Co., Ltd., and Ningbo Aogao Power Consulting Co., Ltd[8] - The company has significant investments in technology and IoT through subsidiaries like Ningbo Sanxing Power IoT Technology Co., Ltd. and Ningbo Sanxing IoT Co., Ltd[8] - Key subsidiaries in the medical field include Ningbo Mingzhou Puhua Pharmaceutical Co., Ltd. and Ningbo Sanxing Medical Research Institute[8] - The company has a presence in the renewable energy sector with subsidiaries like Ningbo Aogao Photovoltaic Power Generation Co., Ltd. and Nansen Solar Energy Co., Ltd. in Brazil[8] - The company acquired 18 new subsidiaries during the reporting period, expanding its consolidated financial statements[68] - The company acquired 100% equity in multiple hospitals, including Huzhou Zhebei Mingzhou Hospital and Quzhou Mingzhou Hospital[121] - The company acquired 100% equity of Huzhou Zhebei Mingzhou Hospital Co., Ltd., Yuyao Mingzhou Rehabilitation Hospital Co., Ltd., Jiaxing Mingzhou Nursing Home Co., Ltd., Quzhou Mingzhou Hospital Co., Ltd., and Quanzhou Mingzhou Rehabilitation Hospital Co., Ltd.[133] - The company acquired 100% equity of multiple hospitals, including Huzhou Zhebei Mingzhou Hospital, Yuyao Mingzhou Rehabilitation Hospital, Jiaxing Mingzhou Nursing Home, Quzhou Mingzhou Hospital, and Quanzhou Mingzhou Rehabilitation Hospital[144] - The company's subsidiary plans to acquire 100% equity of multiple hospitals for RMB 224 million[198] - The company acquired 100% equity of Huzhou Zhebei Mingzhou Hospital Co., Ltd. for a total of RMB 11,200 million[199] - The company acquired 100% equity of Yuyao Mingzhou Rehabilitation Hospital Co., Ltd. for a total of RMB 3,700 million[199] - The company acquired 100% equity of Jiaxing Mingzhou Nursing Home Co., Ltd. for a total of RMB 8,400 million[199] - The company acquired 100% equity of Quzhou Mingzhou Hospital Co., Ltd. for a total of RMB 12,900 million[199] - The company acquired 100% equity of Quanzhou Mingzhou Rehabilitation Hospital Co., Ltd. for a total of RMB 3,759.628 million[199] - The company completed the industrial and commercial registration changes for the five target hospitals in May 2023[199] - The company acquired 2.54% equity of Aokesi Intelligent Technology for RMB 3,759.628 million[199] Financial Performance - Revenue for 2023 reached RMB 11,462,508,357.39, a 25.99% increase compared to 2022[17] - Net profit attributable to shareholders in 2023 was RMB 1,903,702,022.52, up 100.79% year-over-year[17] - Operating cash flow for 2023 was RMB 1,901,306,987.04, a 55.52% increase from 2022[17] - Total assets at the end of 2023 were RMB 21,513,022,906.38, a 32.57% increase compared to 2022[17] - Basic earnings per share for 2023 was RMB 1.35, a 101.49% increase from 2022[18] - Weighted average return on equity (ROE) for 2023 was 18.51%, an increase of 8.19 percentage points from 2022[18] - Q4 2023 revenue was RMB 3,124,748,665.63, the highest among all quarters[20] - Non-operating income in 2023 included RMB 118,212,431.28 from government subsidies[21] - The company recognized RMB 64,406,482.16 in VAT refunds as recurring income due to its sustainability[24] - The company achieved operating revenue of 11.463 billion yuan, a year-on-year increase of 25.99%, and net profit attributable to shareholders of 1.904 billion yuan, a year-on-year increase of 100.79%[27] - The company's gross margin increased to 33.99%, up 5.11 percentage points year-on-year[27] - Company achieved revenue of 11.463 billion yuan, a year-on-year increase of 25.99%[61] - Net profit attributable to shareholders reached 1.904 billion yuan, a year-on-year increase of 100.79%[61] - Operating income from the manufacturing sector was 8.436 billion yuan, with a gross margin of 34.12%, an increase of 5.49 percentage points year-on-year[64] - Operating income from the medical services sector was 2.783 billion yuan, with a gross margin of 31.73%, an increase of 5.01 percentage points year-on-year[64] - Domestic operating income was 9.300 billion yuan, with a gross margin of 33.97%, an increase of 5.53 percentage points year-on-year[64] - International operating income was 1.961 billion yuan, with a gross margin of 32.85%, an increase of 2.98 percentage points year-on-year[64] - Direct sales revenue was 10.258 billion yuan, with a gross margin of 33.20%, an increase of 4.80 percentage points year-on-year[65] - Distribution sales revenue was 1.003 billion yuan, with a gross margin of 39.61%, an increase of 6.95 percentage points year-on-year[65] - Production volume of smart electricity products increased by 12% year-on-year to 25.750 million units/sets[66] - Sales volume of smart electricity products increased by 21% year-on-year to 25.444 million units/sets[66] - Manufacturing sector's main business cost increased by 14.36% year-on-year to 5,558,123,490.30 yuan[67] - Medical services sector's main business cost increased by 25.52% year-on-year to 1,899,717,301.57 yuan[67] - Operating cash flow increased by 55.52% year-on-year to 1,901,306,987.04 yuan[77] - Investment cash flow decreased significantly due to reduced receivables and increased construction investments[77] - Financing cash flow increased to 1,174,529,477.93 yuan due to increased long-term borrowing[77] - Fair value changes in non-current financial assets generated a profit of 100,688,795.43 yuan[79] - Disposal of subsidiaries and other non-current financial assets generated profits of 50,979,269.60 yuan and 27,942,470.54 yuan respectively[79] - Monetary funds increased by 85.93% to 5,452,937,584.98 yuan, mainly due to increased operating cash inflow and long-term loans[80] - Trading financial assets increased by 98.34% to 53,723,860.13 yuan, primarily due to changes in the fair value of Samsung Hong Kong stocks[80] - Inventory increased by 80.70% to 3,256,637,523.09 yuan, driven by scale growth and product/material stockpiling to meet order delivery[80] - Long-term loans surged by 1,544.00% to 2,466,000,000.00 yuan, as the company increased liquidity through additional long-term borrowing[81] - Overseas assets amounted to 1,575,977,257.21 yuan, accounting for 7.33% of total assets[83] - Total restricted assets were 749,963,385.33 yuan, including 410,251,706.66 yuan in monetary funds used as guarantees for bank transactions[85] - Total external investment reached 1,298,996,400 yuan, with 977,626,300 yuan allocated to equity investments through acquisitions and new establishments[87] - The acquisition of Zhebei Mingzhou for 224,000,000 yuan resulted in a profit impact of 5,856,200 yuan[88] - The acquisition of Yuyao Mingzhou Rehabilitation for 112,000,000 yuan resulted in a profit impact of 6,019,900 yuan[88] - The establishment of Quanzhou Mingzhou Rehabilitation for 129,000,000 yuan resulted in a profit impact of 8,639,000 yuan[88] - The company established new rehabilitation medical centers in Suzhou, Jinhua, Wuhu, Hefei, and Foshan with investments of 5,070, 3,900, 3,900, 5,200, and 4,550 thousand RMB respectively, all funded with 65% equity[89] - The company acquired Aokes Intelligent Technology for 3,759.63 thousand RMB, achieving a 100% ownership and generating a profit of 41,042.42 thousand RMB[89] - The company invested 10,000 thousand RMB in establishing Aokes Energy Storage, focusing on new energy technology R&D and equipment manufacturing[90] - The company's total investment in non-equity projects reached 97,762.63 thousand RMB, with a cumulative profit of 40,805.30 thousand RMB[90] - The company invested 32,137.01 thousand RMB in the Power Internet of Things Industrial Park project, with a cumulative investment of 107,975.40 thousand RMB[92] - The company's financial assets, including stocks, private equity funds, and derivatives, had a total fair value of 982,221.47 thousand RMB at the end of the period[93] - The company's stock investment in Modern Dental (HK3600) had an initial cost of 8,585.56 thousand RMB and a year-end fair value of 28,357.71 thousand RMB[94] - The company's commodity futures investments had a year-end fair value of 27,584.46 thousand RMB, accounting for 2.47% of the company's net assets[96] - The company's forward exchange contracts had a total investment of 21,321.15 thousand RMB, with all positions closed by the end of the period[96] - The fair value change of commodity futures contracts in the reporting period was RMB 2.2621 million, calculated based on the settlement prices of corresponding contracts on the Nanhua Futures Exchange[97] - The fair value of forward foreign exchange contracts was determined based on the difference between the contract price and the forward exchange rate at the end of the period[97] - Samsung Intelligent's total assets in 2023 were RMB 2.36837 billion, with a net profit of RMB 236.9189 million[100] - Aux Intelligent Technology's total assets in 2023 were RMB 5.0325527 billion, with a net profit of RMB 410.4242 million[100] - Ningbo Mingzhou Hospital's total assets in 2023 were RMB 1.8831204 billion, with a net profit of RMB 125.4596 million[100] - Mingzhou Medical Group's total assets in 2023 were RMB 2.355199 billion, with a net loss of RMB 28.295 million[100] - Aux Investment's total assets in 2023 were RMB 1.2562357 billion, with a net profit of RMB 142.538 million[100] Business Segments and Market Presence - The smart power distribution and utilization business generated revenue of 8.612 billion yuan, a year-on-year increase of 23.99%, with cumulative orders of 10.494 billion yuan, up 22.09% year-on-year[28] - Overseas orders for the smart power distribution and utilization business reached 4.525 billion yuan, a year-on-year increase of 42.93%, driven by rapid growth in key markets such as Europe, the Middle East, and the Americas[28] - The medical services business achieved revenue of 2.809 billion yuan, a year-on-year increase of 34.57%, with rehabilitation medical services revenue reaching 1.311 billion yuan, up 64.80% year-on-year[32] - The company expanded its hospital network to 28 hospitals, with a total of 8,868 beds, adding 10 new hospitals during the reporting period[33] - The company's overseas sales network now covers over 70 countries and regions, with new factories established in Germany and Mexico[28] - The company successfully delivered multiple smart energy integration projects in Europe and Latin America, achieving a data collection rate of over 99.9% in the Swedish PUMA smart meter project[29] - The company's overseas power distribution business made breakthroughs in the Middle East and Asia-Pacific markets, securing a project with Saudi Arabia's national power company[29] - The company launched new products in the new energy sector, including charging piles and energy storage systems, and developed an integrated "source-grid-storage-charging" business model[30] - The company's DC charging stations cover 60-480kW, with leading performance in recent years[47] - The company launched new products including residential inverters, small commercial string inverters, and residential energy storage inverters in 2023[47] - The company's smart metering products achieved industry-leading collection and line loss rates in overseas markets[47] - The company's photovoltaic box transformers received the first domestic certification, and compact ring main units have been widely used in the Middle East market[47] - The company has established 5 overseas manufacturing bases in Brazil, Indonesia, Poland, Mexico, and Germany, and 5 sales centers in Sweden, Colombia, Nepal, Peru, and Bangladesh, covering over 70 countries and regions[51] - The company's business in the European market covers 15 countries, making it the Chinese manufacturer with the most extensive coverage in Europe[51] - The company has 28 hospitals under its management, with a total of 8,868 beds, including 22 rehabilitation hospitals[57] - The company added 10 new hospitals through self-construction and acquisitions during the reporting period[57] - The company has 31 domestic offices, achieving comprehensive coverage of the power grid and user markets[51] - The company has established a global marketing platform, focusing on five major regional markets: Europe, the Middle East, Asia-Pacific, Africa, and the Americas[48] - The company has successfully passed the CMMI V2.0 L5 international certification, the highest level in the global software field[53] - The company has built a 5G+ industrial internet provincial-level digital factory, equipped with advanced manufacturing facilities such as smart meter production lines and 5G-AGV logistics systems[54] - The company has developed a comprehensive digital operation management platform, integrating systems like SAP, PLM, MES, CRM, WMS, and SRM[56] - The company has established a "large comprehensive base, strong specialized chain" medical system, with Ningbo Mingzhou Hospital becoming a third-level B comprehensive hospital in March 2023[58] Corporate Governance and Leadership - The company's legal representative is Shen Guoying, and its headquarters are located in Ningbo, Zhejiang Province[11] - The company's annual report is disclosed through major financial media outlets such as China Securities Journal, Shanghai Securities News, and Securities Times[14] - The company held a total of 5 shareholder meetings during the reporting period[113] - The company completed the board of directors' re-election, ensuring compliance with legal and regulatory requirements[114] - The company completed the board of supervisors' re-election, effectively supervising business decisions and financial status[115] - The company disclosed 104 temporary announcements in addition to regular reports during the reporting period[118] - The company held 3 performance briefings via video recording in 2023, engaging with investors on governance and strategy[119] - Chairman Shen Guoying holds 650,000 shares with no change during the year[124] - Director Zheng Jianjiang holds 179,306,730 shares with no change during the year[124] - Director Cheng Zhihao reduced his holdings by 172,000 shares to 258,000[124] - Former director Zheng Junda reduced his holdings by 497,375 shares to 50,000[124] - Total shares held by directors and supervisors decreased by 669,375 to 181,328,230[125] - Chairman Shen Guoying received a pre-tax remuneration of

宁波三星医疗电气股份有限公司 内部控制审计报告 2023 年 12 月 31 日 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（hmt//acc mof son an t and the subject of 立信会计师事务所(特殊普通合伙) O CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS 内部控制审计报告 信会师报字[2024]第 ZA12180 号 宁波三星医疗电气股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求,我们审计了宁波三星医疗电气股份有限公司(以下简称三星 医疗）2023年12月31日的财务报告内部控制的有效性。 一、企业对内部控制的责任 内部控制具有固有局限性,存在不能防止和发现错报的可能性。 此外,由于情况的变化可能导致内部控制变得不恰当,或对控制政策 和程序遵循的程度降低,根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 内控审计报告 第1页 立信会计师事务所(特殊普通合伙) china shu lun pan certified public accountants 四、财务 ...

宁波三星医疗电气股份有限公司 审计报告及财务报表 二〇二三年度 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（htm://acc.mof.org 宁波三星医疗电气股份有限公司 审计报告及财务报表 (2023年01月01日至2023年12月31日止) | 目录 | 页次 | | --- | --- | | 审计报告 | 1-6 | | 财务报表 | | | 合并资产负债表和母公司资产负债表 | 1-4 | | 合并利润表和母公司利润表 | 5-6 | | 合并现金流量表和母公司现金流量表 | 7-8 | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | 财务报表附注 | 1-168 | 立信会计师事务所(特殊普通合伙 HINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS 审计报告 信会师报字[2024]第 ZA12179 号 宁波三星医疗电气股份有限公司全体股东: 一、审计意见 我们审计了宁波三星医疗电气股份有限公司(以下简称三星医疗) 财务报表,包括2023年12月31日的合并及母公司资产负债表,2023 年度的合并及母公司利润表、合并及 ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2024-055 宁波三星医疗电气股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据财政部的要求，公司依据上述企业会计准则解释的规定对原会计政策进 行相应变更，并按文件规定的起始日开始执行。 重要内容提示： 二、本次会计政策变更对公司的影响 本次会计政策变更系公司根据财政部发布的《准则解释第 17 号》的相关规 定和要求进行的合理变更，变更后的会计政策能够更加客观、公允地反映公司的 财务状况和经营成果，符合相关法律法规的规定和公司实际情况，不涉及对公司 以前年度的重大追溯调整，不会对公司财务状况、经营成果和现金流量产生重大 影响，不存在损害公司及股东利益的情况。 三、审议程序及独立董事、监事会的结论性意见 本次会计政策变更已经 2024 年 4 月 25 日召开的公司第六届董事会第十二次 会议和第六届监事会第九次会议审议通过，独立董事发表了同意意见，无需提交 股东大会审议。 本次会计政策变更是宁波三星医疗电气股份有限公司（以下简称 ...

Financial Performance - The company's operating revenue for Q1 2024 reached ¥3,024,788,914.34, representing a year-on-year increase of 34.53%[4] - The net profit attributable to shareholders for Q1 2024 was ¥364,254,826.35, reflecting a growth of 35.15% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥375,247,740.28, which is an increase of 41.24% year-on-year[4] - Basic earnings per share for Q1 2024 were ¥0.26, up 35.85% from the previous year[4] - Diluted earnings per share also stood at ¥0.26, reflecting a 35.85% increase year-on-year[4] - The weighted average return on equity was 3.26%, an increase of 0.47 percentage points compared to the previous year[4] - The total comprehensive income for the period was CNY 364,574,945.30, up from CNY 286,068,051.13 in the previous year, marking an increase of about 27.5%[20] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 59.69% to ¥99,347,382.01, primarily due to increased material procurement and expense outlays[4] - The net cash flow from operating activities for Q1 2024 was CNY 99,347,382.01, a decrease from CNY 246,430,917.01 in Q1 2023, indicating a decline of about 59.8%[22] - The company reported a net cash outflow from investing activities of CNY -157,191,155.75 in Q1 2024, contrasting with a net inflow of CNY 19,937,369.33 in Q1 2023[22] - The net cash outflow from financing activities was CNY -213,794,177.42 in Q1 2024, compared to CNY -91,114,391.87 in Q1 2023, indicating a worsening of financing cash flow[23] - The ending cash and cash equivalents balance was ¥2,892,861,874.53, up from ¥120,244,955.68 in Q1 2023, reflecting a significant increase[31] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥21,333,719,480.20, a decrease of 0.83% from the end of the previous year[5] - The total liabilities decreased to ¥10,011,278,037.31 in Q1 2024 from ¥10,359,714,479.63 in Q1 2023, a reduction of approximately 3.4%[16] - The total equity attributable to shareholders increased to ¥11,150,230,331.46 in Q1 2024, compared to ¥11,005,533,096.56 in Q1 2023, marking a growth of 1.3%[16] - The company's total assets as of March 31, 2024, included cash and cash equivalents of CNY 2,960,242,910.11, a significant increase from CNY 552,139,166.87 at the end of 2023[24] Shareholder Information - The total number of common shareholders at the end of the reporting period was 18,642, with the largest shareholder, Aux Group Co., Ltd., holding 32.43% of shares[10] - The largest shareholder, Aux Group Co., Ltd., holds 457,719,653 shares, representing 32.43% of the total shares[10] - The company has no pledged, marked, or frozen shares among the top shareholders[10] Research and Development - Research and development expenses increased to ¥107,606,619.48 in Q1 2024, up from ¥79,357,579.39 in Q1 2023, reflecting a 35.6% rise[19] - Research and development expenses for Q1 2024 were ¥20,207,013.87, an increase from ¥18,672,699.63 in Q1 2023, indicating a focus on innovation[28] Operating Costs - Operating costs for Q1 2024 were ¥2,639,988,293.38, up 36.0% from ¥1,942,265,271.77 in Q1 2023[17] - The company reported a significant increase in sales expenses, which rose to ¥225,615,769.63 in Q1 2024 from ¥139,244,349.83 in Q1 2023, an increase of 62.0%[19] Financial Expenses - The company’s financial expenses increased significantly to ¥18,471,113.41 in Q1 2024 from ¥1,061,995.80 in Q1 2023, indicating a rise in financing costs[19] - The company's financial expenses surged to ¥9,218,239.90 in Q1 2024, compared to ¥2,459,209.29 in Q1 2023, primarily due to increased interest expenses[28] Inventory and Receivables - Accounts receivable increased to RMB 2.305 billion from RMB 2.209 billion year-on-year[14] - The company’s inventory increased to CNY 315,475,307.24 as of March 31, 2024, compared to CNY 271,584,679.16 at the end of 2023, reflecting a growth of approximately 16.1%[24] - The company’s other receivables rose to CNY 2,027,591,627.47 as of March 31, 2024, compared to CNY 1,908,042,131.16 at the end of 2023, indicating an increase of about 6.3%[24]

（一）直接或间接地控制公司的法人（或其他组织）； （二）由上述第（一）项直接或间接控制的除本公司、控股子公司及控制其 他主体以外的法人（或其他组织）； （三）关联自然人直接或间接控制的，或者由关联自然人担任董事（不含同 为双方的独立董事）、高级管理人员的除公司、控股子公司及控制的其他主体以 外的法人（或其他组织）； 宁波三星医疗电气股份有限公司 关联交易决策制度 第一章 总 则 第一条 为规范宁波三星医疗电气股份有限公司（以下简称"公司"）与各 关联人发生的关联交易行为，维护公司及公司全体股东的合法权益，根据《中华 人民共和国公司法》、《中华人民共和国证券法》、《上海证券交易所股票上市 规则》等相关法律、法规、规范性文件以及《宁波三星医疗电气股份有限公司章 程》（以下简称"公司章程"）的规定，结合公司实际情况，制订本制度。 第二条 公司处理关联交易事项，应当遵循下列原则： 第二章 关联人与关联关系 第三条 公司关联人包括关联法人、关联自然人。 第四条 具有下列情形之一的法人（或其他组织），为公司的关联法人： （四）持有公司5%以上股份的法人（或其他组织）及其一致行动人； （五）中国证券监督管理委员会（以下简称 ...

宁波三星医疗电气股份有限公司 2023 年度总裁工作报告 （一）智能配用电板块 报告期内，公司智能配用电业务实现营业收入 86.12 亿元，同比增长 23.99%。 截至报告期末，公司累计在手订单 104.94 亿元，同比增长 22.09%。其中，国内 累计在手订单 59.69 亿元，同比增长 9.94%，主要系电网招标持续领先，同时非 电网及行业大客户业务持续提升；海外累计在手订单 45.25 亿元，同比增长 42.93%，主要系欧洲、中东、美洲等重点市场业务快速增长。 各位董事： 我代表公司管理层向大会作 2023 年度总裁工作报告，提请各位董事审议。 2023 年，公司在董事会的带领下，围绕年度发展目标，立足智能配用电与 医疗服务双主业，抓住行业机遇，扎实推进各项工作。公司经营业绩持续增长， 营业收入和净利润均创上市以来新高。具体汇报如下: 一、2023 年度主要经济指标完成情况： 1、实现营业收入 114.63 亿元，较上年同期增长 25.99%； 2、实现归属上市公司股东的净利润 19.04 亿元，较上年同期增长 100.79%。 二、2023 年度公司经营情况的回顾及分析 1、深耕海外战略：坚持本 ...

宁波三星医疗电气股份有限公司 董事会议事规则 第一章 总则 第一条 为了保护宁波三星医疗电气股份有限公司（以下简称"公司"或"本 公司"）和股东的权益，规范董事的行为，建立规范化的董事会组织架构及运作 程序，保障公司经营决策高效、有序地进行，依照《中华人民共和国公司法》(以 下简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证券法》")、 《上市公司治理准则》、《上市公司独立董事管理办法》、《上海证券交易所股 票上市规则》、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 等有关法律法规以及《宁波三星电气医疗股份有限公司章程》（以下简称"公司 章程"）的规定，制定本规则。 第二条 本规则自生效之日起，即成为规范公司董事会的组织与行为，规范 公司董事长、董事、董事会下设的各职能委员会、董事会秘书职权、职责、权利 与义务的具有法律约束力的文件。 第二章 董事 （三）担任破产清算的公司、企业的董事或者厂长、经理，对该公司、企业 的破产负有个人责任的，自该公司、企业破产清算完结之日起未逾3年； 第三条 董事为自然人，无需持有公司股份，应符合下列要求： （一）最近36个月内未受中国证券监督管理委 ...